Determinación de la asociación del polimorfismo de la Apolipoproteína E (Apo E) relacionada con la presencia de placa aterosclerótica coronaria.

Adriana Moreno Valladares; BSC; Ana Lucia Torres; PhD; Álvaro E. Cartagena; P. MD; María Helena Herrera MD

doi:10.22490/24629448.345

Vol. 4 No. 5 (2006)

Published 2006-06-15

license

Article (before OJS)

The Polimorfism of the Apolipoproteín E (Apo E), Its Important Role in the Lípid Metabolism and the Coronary Illness.

DOI: https://doi.org/10.22490/24629448.345

Adriana Moreno Valladares; BSC Grupo de investigación: Clínico – Genético – Molecular en Dislipoproteínemias Pontificia Universidad Javeriana. Línea Biomarcadores en Enfermedad Cardiovascular

Ana Lucia Torres; PhD Grupo de investigación: Clínico – Genético – Molecular en Dislipoproteínemias Pontificia Universidad Javeriana. Línea Biomarcadores en Enfermedad Cardiovascular

Álvaro E. Cartagena; P. MD Grupo de Medicina Interna y Cardiología. Hospital San Blas. Docente cardiología Universidad Nacional de Colombia. Facultad de Medicina.

María Helena Herrera MD Grupo de Medicina Interna y Cardiología. Hospital Santa Clara.

PDF (Spanish)

Abstract
References

The polimorfism of the Apolipoproteín E (Apo E), it plays a key paper in the lípids metabolism and the coronary illness. This study looked for to identify specific polimorfisms of Apo E for PCR-RFLP and to determine the association in these ways alelicas with the presence of plaque atheroesclerotic. A total of 122 patients was analyzed between 29 and 85 years old, with angina or sharp infart of the miocardial where the occlusion presence was determined by coronary arteriographic. Of the total of analyzed patients, alone 48.4% presented an obstruction degree bigger than 70%. Of these patients 40 were men and 19 women. When establishing the association among obstruction degrees and polimorfismo of ApoE stratified for the genders, a.p. was obtained = 0.0054 for the men and a .p. = 0.977 for the women, what indicates that this association is significant only for the genders masculine. The genotipo E2/2 you associates with they doesn.t witness of obstruction.In conclusion, this study allowed to identifications of allelo E3/3 highly significant in coronary obstruction dependent on gender, confirming what is stated by many authors at national and international level in the sense that genotype E2, could have an important antiatherogenic effect, the same as the isoform E4/4 is not related with coronary obstruction. The effect of the ApoE at cardiovascular level has not been completely clarified yet, what makes it whorty for more studies to demonstrate a more accurate behavior.

keywords: Apolipoprotein E, plaque atheroesclerotic, polimorfism, genotipo.

Khout U, Khot M, Bajzer C, Sapp S, Ohman E, Brener S, Ellis S, Lincoff A, Topol E. 2003. Prevalence of conventional risk factors in patients with coronary heart disease. Jama 290: 898-904.

Kolovou G, Daskalova D, Mikhailidis DP. 2003. Apolipoprotein E polymorphism and atherosclerosis. Angiology 54: 59-71.

Myklebost O, Rogne S. 1988. A physical map of the apoprotein gene cluster on human chromosome 19. Hum Genet 28: 244-7.

Hriday K, Dast J, McPherson G, A.P. B, Sotirios K, Karathanasis J, Breslow L. 1985. Isolation, characterization and mapping to cromosome 19 of the human apolopoprotein E gene. J Biol Chem 260: 6240-7.

Utermann G, Langenbeck U, Beisiegel U, Weber W. 1980. Genetics of the apolipoprotein E system in man. Am J Hum Genet 32: 339-47.

Lai E, Riley J, Purvis I, Roses A. 1998. A 4-Mb High-density single nucleotide polymorphims-based map around human APOE. Genomics 54: 31-8.

Mahley RW. 1988. Apolipoprotein E: Cholesterol transport protein with expanding role in the celll biology. Science 240: 622-30.

Ginsberg HN. 1998. Lipoprotein physiology. Endocrinol Metab Clin North Am 27: 503-19.

Francke U, Brown MS, Goldstei JL. 1984. Assignament of the human gene for the low density lipoprotein receptor tochromosome 10: syntesis for a receptor, a ligando, and a genetics diseases. Proc Natl Acad Sci USA 81: 2826-30.

Pham T, Kodvawala A, Hui DY. 2005. The receptor binding domain of apolipoprotein E is responsible for its antioxidant activity. Biochemistry 44: 777-7582.

Wilson C, Wardell MR, Weisgraber KH, Mahley RW, Agard DA. 1991. Three-dimensional structure of the LDL receptor-binding doamin of human apolipoprotein E. Science 252: 1817-22.

Mahaley RW. 1983. Lipoprotein receptor and cholesterol homeostasis. Biochem Biophys 737: 197-227.

Lenzen HJ, Assman G, Buchwalsky R, Schulte H. 1986. Association of Apo E polymorphism, LDL, and CAD. Clin Chem 32: 778-81.

Staprans I, Pan X, Rapp J, Feingold K. 2005. The role of dietary oxidized cholesterol and oxidized fatty acids in the development of atheroslcerosis. Mol Nutr Food Res 49: 1075-82.

Mahaley RW, Angelyn B. 1984. Type III hiperlipoproteinemia recent insights into the genetic defect of familial dysbetalipoproteinemia. Adv Intern Med 29: 385-411

Pineda M, Matiz H, Rozo R. 2002. Enfermedad coronaria. Bogotá. 757 pp.

Hixson J, Vierner T. 1990. Restriction isotyping of human apoliprotein E by gene amplification an d cleavage wtih HhaI. J Lip Res 31: 545-8.

Bednarska Makaruk M, Broda G, Kurjata P, Rodo M, Roszezynko M, Rymik S, Wehr S. 2001. Apolipoprotein E genotype, lipid levels and coronary heart disease in a Polish population group. Eur J Epidemiol 17: 789-92.

Gamboa R, Hernandéz G, Ramiro P, Zuñiga J, Granados J. 1999. Polimorfismo de la Apolipoproteina E y sus asociaciones con enfermedad cardiovascular. Arch Inst Cardiol Mex 69: 375-82.

Davignon J, Gregg RE, Sing CF. 1988. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8: 1.21.

Elosua R, Ordovas J, Cupples LA, Fox CS, Polak J, Wolf P, D.Agostino RB, O.Donnell J. 2004. Association of APOE genotype with carotid atheroslcerosis in men and women. J Lipid Res 45: 1868-75.

Stengård JH, Weiss KM, Sing CF. 1998. An ecological study of association between coronary heart disease mortality rates in men and the relative frequencies of common allelic variations in the gene coding for apolipoprotein E. Hum Genet 103: 234-441.

Bennouar N, Allami A, Laraqui A, Azeddoug H, El-Kadiri N, Benkouka F, Bendriss A, Ghannam R, Benomar A, Fellat S, Benomar M. 2004. Apolipoprotein E and angiotensinconverting enzyme gene polymorphisms as risk factors of coronary disease. Ann Biol Clin 62: 295-304.

Kolovou G, Yiannakouris N, Hatzivassiliou M, Malakos J, Daskalova D, Hatzigeorgiou G, Cariolou M, DV. C. 2002. Association of apolipoprotein E polymorphism with myocardial infarction in GreeK patients with coronary artery disease. Curr Med Res Opin. 18: 118-24.

Yang Z, Zhu T, Ma G, TYin H, Qian W, Zhang F, Cao K, Ma W. 2001. Apolipoprotein E polymorphism in the early onset of coronary heart disease. Chin Med J 114: 983-5.

Fernandez-Miranda C, Aranda JL, Martin MA, Arenas J, Nunez V, Gomez DlCA. 2004. Apolipoprotein E polymorphism and carotid atherosclerosis in patients with coronary disease. Int J Cardiol. 94: 209-12.

Hirashiki A, Yamada Y, Murase Y, Suzuki Y, Kataoka H, Morimoto Y, Tajika T, Murohara T, Yokota M. 2003. Association of gene polymorphisms with coronary artery disease in low- or high-risk subjects defined by conventional risk factors. J Am Coll Cardiol 42: 1429-37.

Wilson PWF, Myers RH, Larson MG. 1994. Apo E alleles, dyslipidemia, and coronary heart disease: Tha Framingham Offspring Study. Jama 272: 1666-71.

Lehtinen S, Lehtimäki T, Sisto T, Salenius J, Nikkila M, Jokela H, Koivula T, Ebeling F, Ehnholm C. 1995. Apolipoprotein E polymorphism, serum lipids myocardial infarction and severity of angiographically verified coronary artery disease in men and women. Atherosclerosis 114: 83-91.

Mansur A, Annicchino Bizzacchi J, Favaroto D, Avakian S, Cesar L, Ramires J. 2000. Angiotensin converting enzyme an d apolipoprotein s genes polymorphism in coronary artery disease. Clin Cardiol 23: 335-40.

Song Y, Stampfer MJ, Liu S. 2004. Meta-Analysis: Apolipoprotein E Genotypes and Risk for Coronary. Heart Disease 141: 137-47.

license

How to Cite

Moreno Valladares; BSC, A., Torres; PhD, A. L., Cartagena; P. MD, Álvaro E., & Herrera MD, M. H. (2006). The Polimorfism of the Apolipoproteín E (Apo E), Its Important Role in the Lípid Metabolism and the Coronary Illness. NOVA Biomedical Sciences Journal, 4(5), 27-38. https://doi.org/10.22490/24629448.345

Download Citation

Almétricas

Metrics

Metrics Loading ...

Declaración de privacidad.

The Polimorfism of the Apolipoproteín E (Apo E), Its Important Role in the Lípid Metabolism and the Coronary Illness.

How to Cite